Dr. Eva Feldman to address Michigan Israel Business Bridge Nov. 12 in Grand Rapids
Taubman Institute Director Dr. Eva Feldman will address a special event at the Van Andel Institute in Grand Rapids on Monday, Nov. 12. The meeting is a special networking luncheon with the Michigan Israel Business Bridge, a non-profit association that promotes economic growth in Michigan and Israel.
Dr. Feldman, the Russell N. DeJong professor of neurology at the University of Michigan and leader of the first-ever stem cell trial in patients with ALS, will tell the groups about her groundbreaking collaboration with another stem cell pioneer, Benjamin E. Reubinoff, M.D., Ph.D., of Hadassah University Hospital in Jerusalem. Her talk is entitled "U-M and Hadassah: Engineering stem cells to decode a deadly disease."
The luncheon will take place from noon to 1:30 p.m.; registration is required by Nov. 6. The charge for MIBB members is $30 or $35 for non-members. For complete details, click here.
Dr. Eva Feldman: Alfred Taubman as mentor, leader, friend
The source of his greatness lay in his willingness to challenge conventional thinking.
WDIV covers institute's art + science program
Ch. 4 report profiles the collaboration between Taubman Scholar Tom Gardner and artist Osman Khan.
Taubman Scholars: Reflections on Alfred Taubman
Eminent scientists say his curiosity, interest and vision changed the course of medical science.
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.